Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2005 May 17;10220:7380-5. doi: 10.1073/pnas.0502579102.
Show Gene links
Show Anatomy links
Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.
Lippa A
,
Czobor P
,
Stark J
,
Beer B
,
Kostakis E
,
Gravielle M
,
Bandyopadhyay S
,
Russek SJ
,
Gibbs TT
,
Farb DH
,
Skolnick P
.
???displayArticle.abstract???
Benzodiazepines remain widely used for the treatment of anxiety disorders despite prominent, often limiting side effects including sedation, muscle relaxation, and ataxia. A compound producing a robust anxiolytic action comparable to benzodiazepines, but lacking these limiting side effects at therapeutic doses (an anxioselective agent), would represent an important advance in the treatment of generalized anxiety disorder, and perhaps other anxiety disorders. Here we report that the pyrazolo[1,5-a]-pyrimidine, ocinaplon, exhibits an anxioselective profile in both preclinical procedures and in patients with generalized anxiety disorder, the most common of the anxiety disorders. In rats, ocinaplon produces significant muscle relaxation, ataxia, and sedation only at doses >25-fold higher than the minimum effective dose (3.1 mg/kg) in the Vogel "conflict" test. This anticonflict effect is blocked by flumazenil (Ro 15-1788), indicating that like benzodiazepines, ocinaplon produces an anxiolytic action through allosteric modulation of GABA(A) receptors. Nonetheless, in eight recombinant GABA(A) receptor isoforms expressed in Xenopus oocytes, the potency and efficacy of ocinaplon to potentiate GABA responses varied with subunit composition not only in an absolute sense, but also relative to the prototypical benzodiazepine, diazepam. In a double blind, placebo controlled clinical trial, a 2-week regimen of ocinaplon (total daily dose of 180-240 mg) produced statistically significant reductions in the Hamilton rating scale for anxiety scores. In this study, the incidence of benzodiazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ from placebo. These findings indicate that ocinaplon represents a unique approach both for the treatment and understanding of anxiety disorders.
Atack,
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.
2003, Pubmed
Atack,
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.
2003,
Pubmed
Ballenger,
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder.
1991,
Pubmed
Barnard,
International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.
1998,
Pubmed
Chan,
Modulation of neurotransmitter action: control of the gamma-aminobutyric acid response through the benzodiazepine receptor.
1985,
Pubmed
Choi,
Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures.
1977,
Pubmed
De Blas,
Brain GABAA receptors studied with subunit-specific antibodies.
1996,
Pubmed
Feltner,
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
2003,
Pubmed
Greenblatt,
The neuropharmacological actions of amoxapine.
1978,
Pubmed
Griebel,
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.
2001,
Pubmed
Haefely,
Novel anxiolytics that act as partial agonists at benzodiazepine receptors.
1990,
Pubmed
HAMILTON,
The assessment of anxiety states by rating.
1959,
Pubmed
Harvey,
The GABA(A) receptor alpha1 subtype in the ventral pallidum regulates alcohol-seeking behaviors.
2002,
Pubmed
,
Xenbase
Hunkeler,
Selective antagonists of benzodiazepines.
1981,
Pubmed
Johnstone,
Modifying quinolone antibiotics yields new anxiolytics.
2004,
Pubmed
Korpi,
Drug interactions at GABA(A) receptors.
2002,
Pubmed
Lippa,
Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors.
1982,
Pubmed
Lippa,
A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety.
1979,
Pubmed
Lippa,
Benzodiazepine receptors: cellular and behavioral characteristics.
1979,
Pubmed
Liu,
Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors.
1996,
Pubmed
,
Xenbase
Löw,
Molecular and neuronal substrate for the selective attenuation of anxiety.
2000,
Pubmed
Lüddens,
Function and pharmacology of multiple GABAA receptor subunits.
1991,
Pubmed
McKernan,
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.
2000,
Pubmed
McKernan,
Which GABAA-receptor subtypes really occur in the brain?
1996,
Pubmed
Millan,
The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines.
2003,
Pubmed
Pande,
Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
2003,
Pubmed
Park-Chung,
Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites.
1999,
Pubmed
,
Xenbase
Pritchett,
Type I and type II GABAA-benzodiazepine receptors produced in transfected cells.
1989,
Pubmed
Rosahl,
Validation of GABA(A) receptor subtypes as potential drug targets by using genetically modified mice.
2003,
Pubmed
Rudolph,
Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.
1999,
Pubmed
Shannon,
beta-Carboline-3-carboxylate-t-butyl ester: a selective BZ1 benzodiazepine receptor antagonist.
1984,
Pubmed
Stahl,
Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.
2002,
Pubmed
Stephens,
What are the differences between abecarnil and conventional benzodiazepine anxiolytics?
1992,
Pubmed
van Steveninck,
Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol.
1996,
Pubmed
Vogel,
A simple and reliable conflict procedure for testing anti-anxiety agents.
1971,
Pubmed
Wafford,
Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes.
1993,
Pubmed
,
Xenbase
Wisden,
The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon.
1992,
Pubmed